142 related articles for article (PubMed ID: 37860543)
1. Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers.
Fracasso G; Falvo E; Tisci G; Sala G; Colotti G; Cingarlini S; Tito C; Bibbo S; Frusteri C; Tremante E; Giordani E; Giacomini P; Ceci P
Heliyon; 2023 Oct; 9(10):e20770. PubMed ID: 37860543
[TBL] [Abstract][Full Text] [Related]
2. High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.
Falvo E; Damiani V; Conti G; Boschi F; Messana K; Giacomini P; Milella M; De Laurenzi V; Morea V; Sala G; Fracasso G; Ceci P
J Exp Clin Cancer Res; 2021 Feb; 40(1):63. PubMed ID: 33568214
[TBL] [Abstract][Full Text] [Related]
3. Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy.
Falvo E; Arcovito A; Conti G; Cipolla G; Pitea M; Morea V; Damiani V; Sala G; Fracasso G; Ceci P
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33092088
[TBL] [Abstract][Full Text] [Related]
4. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.
Houghton PJ; Lock R; Carol H; Morton CL; Gorlick R; Anders Kolb E; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups CA; Zhang MX; Madden SL; Teicher BA; Smith MA
Pediatr Blood Cancer; 2012 Feb; 58(2):200-9. PubMed ID: 21548007
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone-Loaded Nanoferritin Slows Tumor Growth and Improves the Overall Survival Rate in a Subcutaneous Pancreatic Cancer Mouse Model.
Conti G; Pitea M; Ossanna R; Opri R; Tisci G; Falvo E; Innamorati G; Ghanem E; Sbarbati A; Ceci P; Fracasso G
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829851
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S; Serwer L; DuPage A; Elkins K; Chauhan N; Ravn M; Buchanan F; Wang L; Krimm M; Wong K; Sagert J; Tipton K; Moore SJ; Huang Y; Jang A; Ureno E; Miller A; Patrick S; Duvur S; Liu S; Vasiljeva O; Li Y; Henriques T; Badagnani I; Jeffries S; Schleyer S; Leanna R; Krebber C; Viswanathan S; Desnoyers L; Terrett J; Belvin M; Morgan-Lappe S; Kavanaugh WM; Richardson J
Mol Cancer Ther; 2022 Aug; 21(8):1326-1336. PubMed ID: 35666803
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
10. Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.
Vine KL; Indira Chandran V; Locke JM; Matesic L; Lee J; Skropeta D; Bremner JB; Ranson M
Curr Cancer Drug Targets; 2012 Jan; 12(1):64-73. PubMed ID: 22111834
[TBL] [Abstract][Full Text] [Related]
11. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
13. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
16. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
17. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
18. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
[TBL] [Abstract][Full Text] [Related]
19. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
